MDM2 and MDM4: p53 regulators as targets in anticancer therapy
- 31 August 2007
- journal article
- review article
- Published by Elsevier BV in The International Journal of Biochemistry & Cell Biology
- Vol. 39 (7-8), 1476-1482
- https://doi.org/10.1016/j.biocel.2007.03.022
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Mouse Mutants Reveal that Putative Protein Interaction Sites in the p53 Proline-Rich Domain Are Dispensable for Tumor SuppressionMolecular and Cellular Biology, 2007
- Monoubiquitylation promotes mitochondrial p53 translocationThe EMBO Journal, 2007
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Acetylation of the p53 DNA-Binding Domain Regulates Apoptosis InductionMolecular Cell, 2006
- MDMX regulation of p53 response to ribosomal stressThe EMBO Journal, 2006
- Critical role for Daxx in regulating Mdm2Nature, 2006
- Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell deathCell Death & Differentiation, 2006
- Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fateThe Journal of cell biology, 2006
- Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3Cancer Research, 2006
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004